P109 Psoriasis care in a specialized academic psoriasis centre

Abstract Psoriasis, currently referred to as psoriasis disease, is among the most frequent human chronic inflammatory skin diseases. Both pathogenic knowledge and clinical management are very much advanced over the last two decades and are superior compared with most other dermatological diseases. This is mirrored by several national and international clinical guidelines. Yet, patient care is still grossly varying among countries and regions within individual countries. Here data from a single psoriasis centre are presented including 869 inpatients and outpatients. Thirty percentage of the patients got their first diagnosis between the age of 18 and 40 years with plaque psoriasis at 79.3%, scalp psoriasis at 25%, inverse psoriasis 16.2% and pustular psoriasis 9%. The most affected area was the trunk (69.3%), followed by the extremities 58.1%; 21.3% of patients had confirmed Psoriasis-arthritis. Almost 50% had at least one comorbidity, arterial hypertension being most frequent with 30.7%, adiposities (17.3%), hyperlipidaemia (14.5%), hypothyroid disease (8.9%) and depression (6.7%). With regard to therapy, 38% of patients had topical treatment and 45.2% any ultraviolet therapy (narrowband UVB 23.8%, bath PUVA 14.8%). However, 45% used systemic biologic treatment, 12% were on conventional systemic agents and 5% were on small molecular antagonists. Among current systemic agents, ustekinumab was the most frequently used (11.9%), followed by secukinumab (10.6%), adalimumab 7.1% and methotrexate (5.5%). The most frequently used systemic drugs during the drug history were methotrexate (26.2%), fumarates (24.5%) and ustekinumab (20.4%). Compared with earlier data from this centre, there is a distinct increase in systemically treated patients and those on biologics over time. These data compare well with other published studies and reflect the patient composition and high portion of systemically treated patients of an academic medical centre.